ONCOLOGY
Cancer: A Devastating Global Disease
Cancer is a disease that has left a profound mark worldwide. With more than 9.6 million deaths in 2018, it has become the second leading cause of death globally. This alarming fact highlights the need to effectively address this disease and provide adequate access to healthcare. The burden of morbidity associated with cancer continues to rise, placing immense physical, emotional, and financial strain on families, communities, and healthcare systems.
Challenges in Low- and Middle-Income
Health Systems Unfortunately, many healthcare systems in low- and middle-income countries are inadequately prepared to address the burden of cancer morbidity. These systems often face significant challenges, such as a lack of resources, limited infrastructure, and a shortage of specialized medical personnel.
THE IMPORTANCE OF IMPROVING ACCESS TO ONCOLOGICAL CARE
The pharmaceutical industry plays a crucial role in improving access to oncological care worldwide. Recognizing the importance of this cause, pharmaceutical companies are committed to the development and availability of effective treatments for cancer patients.
Research and development of new oncological drugs have become a priority for the pharmaceutical industry. These companies invest significant resources in the search for innovative and personalized therapies that offer better outcomes and a higher quality of life for patients. Additionally, they focus on optimizing existing treatments and seeking new therapeutic combinations and formulations to enhance efficacy and reduce side effects.
Furthermore, the pharmaceutical industry seeks to establish partnerships with medical organizations and healthcare systems to improve cancer diagnosis and treatment infrastructure and capabilities. This includes collaboration in creating specialized oncology centers, training healthcare professionals in managing oncological diseases, and supporting clinical research to identify new biomarkers and more effective therapies.
The importance of improving access to oncological care not only lies in the direct benefit to patients but also the impact on society as a whole. Cancer not only affects people’s health but also their emotional and financial well-being. By improving access to quality treatments, the economic and emotional burden on families and communities is reduced.
THE FUNDAMENTAL ROLE OF ONCOLOGY IN THE PHARMACEUTICAL INDUSTRY
Oncology has become of paramount importance in the pharmaceutical industry, becoming the most prominent therapeutic area in terms of global sales. This fact is not surprising, considering the increasing incidence of cancer and the urgent need for effective treatments.
Projections indicate that the field of oncology will experience double-digit annual growth until 2027. This encouraging forecast is partly due to the launch of approximately 100 new treatments during this period. These advancements reflect the commitment and dedication of the pharmaceutical industry in the fight against this devastating disease that affects millions of people worldwide.
The increase in research and development of oncological therapies demonstrates the importance given to this area within the pharmaceutical industry. Pharmaceutical companies are investing significant resources in discovering new molecules, conducting clinical trials, and seeking more effective and personalized treatments for different types of cancer.
This focus on oncology aims not only to provide innovative treatment options but also to improve the quality of life for oncology patients. Efforts are being made to develop more specific and less invasive therapies, as well as to identify biomarkers that allow for more precise treatment selection and better prediction of therapeutic response.
SUCCESS STORIES
- Breast Cancer: Launch of two innovative product presentations for a leading product
- CAR-T: Patient referral program to reference centers.
- Launch of innovative brand for the treatment of neuroendocrine tumors
- Omnichannel promotion of a leading product in the treatment of certain gastroenteropancreatic and neourendocrine tumors and patients with acromegaly with results of change in trend returning to positive growth.
- Omnichannel promotion of a product indicated for the treatment of advanced renal cell carcinoma (RCC) and Soft Tissue Sarcoma (STS)
- Prostate cancer: omnichannel medical service throughout Latam to present the results of a new clinical study through a team of virtual MSLs
- Comprehensive management as foreign medication of oncological products for cell lymphoma treatments.
BE PART OF OUR TEAM
WORK WITH US
We are an innovative laboratory that adds value to patients through the marketing of high-quality and trusted medications.
If you are passionate about this field and are looking to be part of a team committed to excellence, we invite you to join us.
AVANZIA PHARMA
CONTACT US